文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

地塞米松对机械通气COVID-19患者呼吸机相关性肺炎发生率的影响:一项倾向匹配队列研究

Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study.
PubMed 文献 · Crit Care · 2022-06-13
一句话结论倾向匹配队列显示,机械通气COVID-19患者使用地塞米松6 mg/日静脉10天者VAP风险增加(RR 1.61),ICU住院时间和有创机械通气时间更长,死亡率无差异。

该倾向匹配回顾性队列研究纳入意大利伦巴第4个COVID-19 ICU的739例成人机械通气COVID-19患者,按1:1匹配为DEXA+组(地塞米松6 mg/日静脉10天)与DEXA-组各158例。DEXA+组VAP发生率56% vs 34%(RR 1.61,p=0.0001),VAP风险HR 1.81(p=0.0003),ICU住院时间和有创机械通气时间更长,死亡率相似(RR 1.17,p=0.3332)。VAP中28%由多重耐药菌引起,VAP本身与住院时间近翻倍及死亡率升高相关(RR 1.64,p=0.040)。结论提示重症COVID-19患者VAP风险高,糖皮质激素治疗增加该风险。

要点

  • 匹配后DEXA+组VAP 89/158(56%)vs DEXA-组55/158(34%),RR 1.61(1.26-2.098),p=0.0001。
  • DEXA+组VAP风险HR 1.81(1.31-2.50),p=0.0003;粗VAP发生率49.58 vs 31.65/1000机械通气日,IRR 1.57(1.55-1.58),p<0.0001。
  • DEXA+组ICU住院时间和有创机械通气时间更长,死亡率相似(RR 1.17(0.85-1.63),p=0.3332)。
  • 41例(28%)VAP由多重耐药菌引起;VAP与ICU及住院时间、有创机械通气近翻倍及死亡率升高相关(RR 1.64(1.02-2.65),p=0.040)。

适用人群与场景

  • 2020年2月24日至12月31日意大利伦巴第4个COVID-19专属ICU收治的成人连续机械通气COVID-19患者。
  • 分为DEXA+组(接受低剂量皮质类固醇:地塞米松6 mg/日静脉10天)与DEXA-组(未接受皮质类固醇)。

处置流程与药物剂量

  • DEXA+组自入院起接受地塞米松6 mg/日静脉给药,持续10天。

研究设计与关键结果

  • 倾向匹配回顾性队列研究,纳入739例,1:1倾向评分匹配后DEXA+组与DEXA-组各158例;匹配变量包括年龄、体重、PEEP水平、PaO2/FiO2比值、非呼吸序贯器官衰竭评估(SOFA)评分、Charlson合并症指数(CCI)、入院时C反应蛋白血浆浓度、性别及入院医院(精确匹配)。
  • DEXA+组89例(56%) vs DEXA-组55例(34%)发生VAP,RR 1.61(1.26-2.098),p=0.0001;两组自住院、ICU入住及插管至VAP的时间相似。
  • DEXA+组粗VAP发生率49.58(49.26-49.91) vs 31.65(31.38-31.91)VAP*1000/机械通气日,IRR 1.57(1.55-1.58),p<0.0001;VAP风险HR 1.81(1.31-2.50),p=0.0003。
  • DEXA+组ICU住院时间和有创机械通气时间更长,死亡率相似(RR 1.17(0.85-1.63),p=0.3332)。
  • VAP病原体革兰阳性菌(多为金黄色葡萄球菌)与革兰阴性菌(多为肠杆菌目)比例相似;41例(28%)VAP由多重耐药菌引起。
  • VAP与ICU及住院时间、有创机械通气时间近乎翻倍相关,并伴死亡率升高(RR 1.64(1.02-2.65),p=0.040),两组间无差异。

证据类型、等级与局限

  • 证据类型:倾向匹配回顾性队列研究。
  • 试验注册:NCT04388670,2020年5月14日回顾性注册。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,重症COVID-19患者VAP风险高,常由多重耐药菌引起,且该风险因皮质类固醇治疗而增加。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To assess the impact of treatment with steroids on the incidence and outcome of ventilator-associated pneumonia (VAP) in mechanically ventilated COVID-19 patients.

DESIGN: Propensity-matched retrospective cohort study from February 24 to December 31, 2020, in 4 dedicated COVID-19 Intensive Care Units (ICU) in Lombardy (Italy).

PATIENTS: Adult consecutive mechanically ventilated COVID-19 patients were subdivided into two groups: (1) treated with low-dose corticosteroids (dexamethasone 6 mg/day intravenous for 10 days) (DEXA+); (2) not treated with corticosteroids (DEXA-). A propensity score matching procedure (1:1 ratio) identified patients' cohorts based on: age, weight, PEEP Level, PaO2/FiO2 ratio, non-respiratory Sequential Organ Failure Assessment (SOFA) score, Charlson Comorbidity Index (CCI), C reactive protein plasma concentration at admission, sex and admission hospital (exact matching).

INTERVENTION: Dexamethasone 6 mg/day intravenous for 10 days from hospital admission.

MEASUREMENTS AND MAIN RESULTS: Seven hundred and thirty-nine patients were included, and the propensity-score matching identified two groups of 158 subjects each. Eighty-nine (56%) DEXA+ versus 55 (34%) DEXA- patients developed a VAP (RR 1.61 (1.26-2.098), p = 0.0001), after similar time from hospitalization, ICU admission and intubation. DEXA+ patients had higher crude VAP incidence rate (49.58 (49.26-49.91) vs. 31.65 (31.38-31.91)VAP*1000/pd), (IRR 1.57 (1.55-1.58), p < 0.0001) and risk for VAP (HR 1.81 (1.31-2.50), p = 0.0003), with longer ICU LOS and invasive mechanical ventilation but similar mortality (RR 1.17 (0.85-1.63), p = 0.3332). VAPs were similarly due to G+ bacteria (mostly Staphylococcus aureus) and G- bacteria (mostly Enterobacterales). Forty-one (28%) VAPs were due to multi-drug resistant bacteria. VAP was associated with almost doubled ICU and hospital LOS and invasive mechanical ventilation, and increased mortality (RR 1.64 [1.02-2.65], p = 0.040) with no differences among patients' groups.

CONCLUSIONS: Critically ill COVID-19 patients are at high risk for VAP, frequently caused by multidrug-resistant bacteria, and the risk is increased by corticosteroid treatment.

TRIAL REGISTRATION: NCT04388670, retrospectively registered May 14, 2020.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Scaravilli V, Guzzardella A, Madotto F, et al. Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study. Crit Care. 2022. PMID: 35698155. doi:10.1186/s13054-022-04049-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。